• EPZ5676: DOT1L Inhibitor Workflows for MLL Leukemia Research

  2026-06-23

  EPZ5676, a potent and selective DOT1L inhibitor, empowers researchers to dissect H3K79 methylation and target MLL-rearranged leukemias with nanomolar precision. This guide details experimental workflows, troubleshooting strategies, and translational insights from recent advances in epigenetic therapy.

• GW4064 and FXR: Unlocking Translational Metabolic Pathways

  2026-06-23

  This thought-leadership article explores the mechanistic and translational significance of FXR activation in metabolic research, highlighting GW4064’s unique utility and limitations. Drawing on recent studies, including the interplay between tight junction integrity, bile acid homeostasis, and FXR-mediated transporter regulation, the piece provides strategic guidance for translational researchers aiming to model, modulate, and mechanistically dissect metabolic and cholestatic liver injury. The discussion is anchored by data-driven insights, competitive positioning, and a forward-looking vision for FXR-targeted research tools.

• FITC-Concanavalin A (ConA) Conjugate: Technical Lab Guidance

  2026-06-22

  FITC-Concanavalin A (ConA) Conjugate enables direct visualization and quantification of α-D-glucose and α-D-mannose residues on cell surfaces in immunofluorescence and flow cytometry workflows. It is not suitable for non-carbohydrate detection or use outside its defined storage and stability conditions. This reagent provides a streamlined, fluorescence-based approach for glycobiology research requiring specific cell surface carbohydrate detection.

• FITC-Concanavalin A (ConA) Conjugate: Technical Workflow Gui

  2026-06-22

  FITC-Concanavalin A (ConA) Conjugate enables direct, fluorescence-based detection of cell surface α-D-glucose and α-D-mannose residues for immunofluorescence and flow cytometry workflows. It is not suitable for non-carbohydrate targets or for use outside its defined storage and stability conditions. Proper protocol setup and QC are required to ensure result reliability.

• Erastin: Precision Ferroptosis Inducer for Cancer Biology Re

  2026-06-21

  Erastin enables targeted induction of ferroptosis, unlocking new strategies in cancer biology research, especially for RAS/BRAF-mutant tumors. This guide details optimized protocols, advanced applications, and troubleshooting—empowering scientists to maximize reproducibility and insight in oxidative stress and cell death assays.

• DOT1L Inhibition Primes Innate Immunity in Multiple Myeloma

  2026-06-20

  A recent study demonstrates that DOT1L inhibition reprograms innate immune signaling and potentiates the efficacy of immunomodulatory drugs in multiple myeloma. These findings reveal novel epigenetic dependencies and suggest that DOT1L is a promising therapeutic target for enhancing immune-based treatments in hematologic malignancy.

• PDHA1 Succinylation Drives Immune Escape in Cholangiocarcino

  2026-06-19

  A recent study reveals that succinylation of PDHA1 at lysine 83 in cholangiocarcinoma reprograms tumor metabolism, leading to alpha-ketoglutaric acid accumulation and suppression of macrophage antigen presentation. Targeting this pathway with CPI-613 enhances chemotherapy efficacy, offering new strategies for overcoming resistance.

• Host GSK3 Inhibition as an Alternative Strategy for Tubercul

  2026-06-19

  The referenced iScience study demonstrates that inhibiting host glycogen synthase kinase 3 (GSK3) in macrophages significantly restricts the intracellular growth of Mycobacterium tuberculosis. By highlighting host-directed therapy as a feasible adjunct or alternative to conventional antibiotics, this research provides a new mechanistic foundation for tackling persistent and drug-resistant TB.

• DOT1L Inhibition Boosts Immunomodulatory Drug Response in My

  2026-06-18

  This study uncovers that DOT1L inhibition in multiple myeloma (MM) cells not only activates innate immune signaling but also enhances the efficacy of immunomodulatory agents such as lenalidomide. By delineating the molecular pathways involved—including STING-mediated interferon signaling and IRF4-MYC suppression—the work positions DOT1L as a promising epigenetic target for improving MM therapeutic responses.

• G007-LK Tankyrase 1/2 Inhibitor: Optimizing Wnt & Hippo Path

  2026-06-18

  G007-LK stands out as a nanomolar-potency tankyrase 1/2 inhibitor, uniquely enabling precision studies of Wnt/β-catenin and Hippo pathway modulation in cancer models. Its robust selectivity, well-validated protocols, and accessible troubleshooting support make it an essential tool for dissecting APC mutation-driven oncogenic signaling.

• Diterpene Glycosides Target DHT-Driven BPH via Androgen and

  2026-06-17

  This study demonstrates that diterpene glycosides from Fructus Rubi significantly ameliorate benign prostatic hyperplasia (BPH) in rat and cell models by modulating androgen receptor and TGF-β/Smad signaling. These findings highlight a multitarget approach that directly interferes with DHT-induced prostate cell proliferation and epithelial-mesenchymal transition, suggesting novel therapeutic avenues for BPH.

• High-Throughput BBB Permeability: LLC-PK1-MOCK/MDR1 Model Ad

  2026-06-17

  The reference study introduces a high-throughput in vitro blood-brain barrier (BBB) model that integrates LLC-PK1-MOCK/MDR1 cells with lysosomal trapping correction, yielding improved predictive accuracy for CNS drug permeability. This innovation enables earlier, more reliable prioritization of drug candidates for brain penetration, streamlining preclinical neuropharmacology research.

• Live-Dead Cell Staining Kit: Precision in Cell Viability Ass

  2026-06-16

  The Live-Dead Cell Staining Kit, leveraging Calcein-AM Propidium Iodide staining, delivers superior discrimination of viable and non-viable cells in complex experimental systems. This article unpacks workflow optimizations, troubleshooting, and advanced applications that distinguish this dual-fluorescent approach from legacy viability methods.

• BMP4-GPX4 Axis Reduces Ferroptosis in NMDA-Induced Glaucoma

  2026-06-16

  This study demonstrates that activation of the BMP4-GPX4 pathway mitigates ferroptosis in retinal ganglion cells and enhances their differentiation after retinal stem cell transplantation in a mouse model of high intraocular pressure glaucoma. The work advances understanding of molecular neuroprotection mechanisms and provides new strategies for improving stem cell-based therapies in glaucoma.

• Y-27632 Dihydrochloride: Mechanistic Insights in Cancer and

  2026-06-15

  Explore the advanced mechanistic roles of Y-27632 dihydrochloride, a potent ROCK inhibitor, in cancer and stem cell research. This article delivers a unique, evidence-driven perspective that bridges cytoskeletal modulation with emerging findings in tumor progression.

16564 records 1/1105 page Next 12345 下5页 Last page